ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,928.53
-0.71%
US Tech 100
20,676.00
-1.08%
Dow Jones
42,705.42
-0.67%
Brent Oil
74.415
1.07%
Bitcoin
92,282.18
-1.32%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genenta Science SPA (GNTA)

  7. Genenta Science SPA (GNTA) News

Genenta Science SPA

Genenta Science SPA (GNTA)

NASDAQ
5.398
0.518
( 10.61% )
Updated: 12:08:12
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

GNTA News

Official News Only

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
December 20 2024
GNTA (10.61%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
December 20 2024
GNTA (10.61%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
December 13 2024
GNTA (10.61%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 14 2024
GNTA (10.61%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 29 2024
GNTA (10.61%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 20 2023
GNTA (10.61%)

GNTA Discussion

View Posts
Monksdream Monksdream 1 week ago
GNTA under $6
👍️0
Monksdream Monksdream 1 week ago
GNTA under $5
👍️0
Monksdream Monksdream 2 months ago
GNTA under $6
👍️0
Awl416 Awl416 5 months ago
What leaked
👍️0
Monksdream Monksdream 8 months ago
GNTA under $3
👍️0
Luckypennyman Luckypennyman 2 years ago
FDA’s decision to grant Orphan Drug Designation to Temferon









glta
👍️0
makinezmoney makinezmoney 2 years ago
$GNTA: Just got a $15 PriceTarget upgrade.

From here $5, looks like its gonna be a nice ride up


GO $GNTA
👍️0
conix conix 3 years ago
Maxim starts Genenta Science at buy; PT $21

Stephen Kilmer

January 13, 2022

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

“Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

“Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.
👍️0
asser_al7ob asser_al7ob 3 years ago
is this genta that we have before, it is coming back after years
👍️0
Phosphene Phosphene 3 years ago
Clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class
gene and cell therapies in cancer.

Genenta uses gene-based cytokine delivery
to activate the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

https://www.genenta.com/

TEM-GBM_001

👍️0

Your Recent History

NASDAQ
GNTA
Genenta Science
BOV
VALE3
VALE ON
BIT
NSCIT0542257
InnovativeRFK
BIT
S29778
Societe Generale Effekten
BIT
YIV
Societe Generale Accepta...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads